Vaccination News Home Page            Scandals            subscribe Vaccination NewsLetter

http://archpedi.ama-assn.org/cgi/content/abstract/157/5/443

JAMA & ARCHIVES
Arch Pediatr Adolesc Med
SEARCH THIS JOURNAL
GO TO ADVANCED SEARCH
HOME CURRENT ISSUE PAST ISSUES COLLECTIONS CONTACT US HELP

 
Vol. 157 No. 5, May 2003 TABLE OF CONTENTS
  Featured Link
 •  E-mail Alerts
Article
 Article Options
 • Full text
 • PDF
 • Send to a Friend
 • Readers Reply
   •Submit a reply
 • Related articles in this issue
 • Similar articles in this journal
 Literature Track
 • Add to File Drawer
 • Download to Citation Manager
 • PubMed citation
 • Articles in PubMed by
   •Marshall GS
   •Woods CR
 • Contact me when this article is cited
 Topic Collections
 • Infectious Diseases
 • Bacterial Infections
 • Collection E-mail Alerts


Antibodies Reactive to Rickettsia rickettsii Among Children Living in the Southeast and South Central Regions of the United States

Gary S. Marshall, MD; Gordon G. Stout, BS; Richard F. Jacobs, MD; Gordon E. Schutze, MD; Helene Paxton, MS; Steven C. Buckingham, MD; John P. DeVincenzo, MD; Mary Anne Jackson, MD; Venusto H. San Joaquin, MD; Steven M. Standaert, MD; Charles R. Woods, MD; and the Tick-Borne Infections in Children Study (TICS) Group
 

Arch Pediatr Adolesc Med. 2003;157:443-448.

Background  The reported annual incidence of Rocky Mountain spotted fever in the United States is 2.2 per million, but studies have suggested that human infection with Rickettsia rickettsii may be more common. This study estimated the prevalence of antibodies reactive to R rickettsii among children living in the southeastern and south central United States.

Study Design  Approximately 300 specimens were obtained from children at each of 7 pediatric referral centers (N = 1999). Serum was tested for R rickettsii antibodies by means of indirect immunofluorescence antibody assay. Three different cutoff titers (>=64, >=128, and >=256) represented increasing levels of stringency to define positive specimens.

Results  Overall, 12.0% of children had R rickettsii antibody titers of at least 64; 7.3%, at least 128; and 4.3%, at least 256. Strong relationships were seen between increasing age and seroprevalence at each cutoff titer. Remarkably, 6.4% of children aged 13 to 17 years had titers of at least 256. Age-adjusted seroprevalence rates at titers of at least 64 varied from 21.9% in Little Rock, Ark, to 3.5% in Louisville, Ky. At titers of at least 256, seroprevalence ranged from 7.7% in Nashville, Tenn, to 1.8% in Winston-Salem, NC. Only site and age group were strong predictors of seropositivity; a weak association was seen with nonurban residence.

Conclusions  To our knowledge, this is the largest serosurvey of rickettsial infection in children in the United States. Within the limitations of the immunofluorescence antibody assay, these data suggest that infections with R rickettsii or antigenically related spotted-fever group rickettsiae may be common and subclinical. The results also have implications for the interpretation of single immunofluorescence antibody assay titers in children with suspected Rocky Mountain spotted fever.


From the Departments of Pediatrics, University of Louisville School of Medicine, Louisville, Ky (Dr Marshall and Mr Stout), University of Arkansas for Medical Sciences, Little Rock (Drs Jacobs and Schutze), University of Tennessee Health Sciences Center, Memphis (Drs Buckingham and DeVincenzo), University of Missouri, Kansas City (Dr Jackson), University of Oklahoma Health Sciences Center, Oklahoma City (Dr San Joaquin), and Wake Forest University School of Medicine, Winston-Salem, NC (Dr Woods); PanBio InDx, Inc, Baltimore, Md (Ms Paxton); and Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn (Dr Standaert).

 

RELATED ARTICLES IN ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE

This Month in Archives of Pediatrics & Adolescent Medicine
Arch Pediatr Adolesc Med. 2003;157:413.
FULL TEXT  

 

HOME | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | CONTACT US | HELP
© 2003 American Medical Association. All Rights Reserved.

 

Vaccination News Home Page

 

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.